NA
TGTX icon

Navellier & Associates’s TG Therapeutics TGTX Stock Holding History

Navellier & Associates’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Hold
29,290
– – 0.13% 147
2026
Q1 		$973K Buy
+29,290
New +$873K 0.1% 151

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Navellier & Associates's TGTX Position: Q2 2026 in Review

Navellier & Associates held its TG Therapeutics (TGTX) position steady in Q2 2026 at 29,290 shares worth $1.61M. The position accounts for 0.13% of the portfolio, ranked #147.

Navellier & Associates first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Navellier & Associates held 29,290 shares of TG Therapeutics worth $1.61M as of Q2 2026.
  • Navellier & Associates left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up 0.13% of Navellier & Associates's portfolio in Q2 2026, its #147 holding.
  • Navellier & Associates first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.